ent-Ivabradine hydrochloride
CAS : 148849-68-7
Ref. 3D-FI167360
1mg | Arrêté | ||
2mg | Arrêté | ||
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté |
Informations sur le produit
- 2H-3-Benzazepin-2-one, 3-[3-[[(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-, monohydrochloride, (R)-
- 2H-3-Benzazepin-2-one, 3-[3-[[[(7R)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-, hydrochloride (1:1)
- Bicyclo[4.2.0]octane, 2H-3-benzazepin-2-one deriv.
- (R)-3-(3-(((3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-4,5-dihydro-1H-benzo[d]azepin-2(3H)-one hydrochloride
Ivabradine hydrochloride is a drug that belongs to the class of anti-anginal agents. It is an inhibitor of the enzyme, potassium channel IKr, which prolongs the time for myocardial repolarization and reduces the rate and magnitude of ventricular tachycardia (VT) and ventricular fibrillation (VF). Ivabradine hydrochloride has been shown to have significant effects on clinical syndrome in patients with heart failure. This drug also has a dynamic effect on telecommunication. Ivabradine hydrochloride works by shifting the base line upward, which lowers the pharmacological as well as increases its effectiveness.